Study Evaluating the Efficacy and Safety of Artesunate

Inclusion Criteria: * Be at least 18 years of age * Recipient of a solid organ transplant (kidney, lung, heart, or liver) * Have a documented CMV infection * Have CMV DNAemia * Require IV GCV or oral VGCV * Be washed out from any anti-CMV antiviral drugs * Have all the following results as part of screening laboratory assessments * Have life expectancy of ≥ 12 weeks * Be willing and have an understanding and ability to fully comply with the study * If female use birth control Exclusion Criteria: * Have taken IV GCV or oral VGC daily for \>8 days * Have refractory CMV infection or disease * Have CMV antiviral drug resistance * Have a known hypersensitivity to artesunate, GCV, or VGCV * Pregnant (or expecting to conceive) or nursing * Have severe liver disease * Require ongoing treatment with or an anticipated need for treatment with drugs with known interactions with artesunate or GCV * Taking any another investigational drug with anti-CMV activity